Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE3
Clinical Trials Related to Follicular Lymphoma
Related studies linked through entity extraction aliases.
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
- Status
- RECRUITING
- Phase
- PHASE2
Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
B-cell Chronic Lymphoid Malignancies Markers
- Status
- UNKNOWN
- Phase
- N/A
Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status
- Status
- UNKNOWN
- Phase
- PHASE2
Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- NA
Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region
- Status
- COMPLETED
- Phase
- N/A
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
- Status
- COMPLETED
- Phase
- N/A
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study
- Status
- UNKNOWN
- Phase
- PHASE4
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Status
- RECRUITING
- Phase
- PHASE1
First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Study of Copanlisib and Ketogenic Diet
- Status
- TERMINATED
- Phase
- PHASE2